Preventing Weight Gain and Diabetes in People with HIV in South Africa

项目总结 背景：肥胖和糖尿病是艾滋病毒携带者发病率和死亡率的重要危险因素 (PWH)，特别是在撒哈拉以南非洲，那里的卫生系统已经在努力应对艾滋病毒的快速上升 代谢性疾病。以多洛替格雷(DTG)为基础的抗逆转录病毒疗法(ART)最近已被采用为 该地区大部分地区的一线养生法，尽管有证据表明它与超重有关。而当 HIV关怀系统提供了一个有能力的健康系统平台，肥胖和糖尿病的预防不是当前的 护理重点范例。候选人：我是麻省总医院传染病方面的临床研究员 医院和一名内科科学家，在全球卫生流行病学方面受过博士级别的培训，并有很强的跟踪能力 发表的观察性研究的记录。然而，我最近照顾威尔斯亲王医院的经历使我 渴望在设计和执行干预试验以预防代谢性疾病方面获得新技能 人口。我的首要职业目标是成为一名独立的、由NIH资助的内科科学家 在治疗艾滋病毒的代谢并发症以及开发和测试临床干预措施方面的专业知识 预防这些并发症。培训：为了实现研究的独立性，我需要在以下方面进行额外的培训 1)肥胖医学和糖尿病预防，2)基于行为模型的干预设计，3) 开展和分析预防艾滋病毒代谢并发症的临床试验。导师：我的培训和 研究计划将由我的主要导师Mark Siedner博士监督，他得到了广泛的指导 在南非经历并进行观察性队列研究和临床试验。珍妮特·洛博士 (肥胖医学和糖尿病预防)，Christina Psaros(基于行为模型的干预设计)， 和黛博拉·韦克斯勒(临床试验的进行和分析)将担任共同导师，提供额外的 专注于专业知识。我还将收到我的科学顾问委员会的年度反馈，其中包括Dr。 Rochelle Walensky，Naomi Levitt，Robert Parker，Till Bärnighausen。研究：在我的指导下 导师团队，我将探索DTG在南非PWH中的代谢效应，并开发和试点 通过三个具体目标来减少这些并发症的干预：1)确定行为 在南非，体重变化和糖耐量异常与PWH向基于DTG的抗逆转录病毒治疗过渡的相关性； 2)开发一种可接受的、与环境相适应的干预措施，以防止体重增加和糖尿病 PWH对南非基于DTG的抗逆转录病毒治疗的研究；以及3)进行因子随机可行性研究 以DTG为基础的抗逆转录病毒治疗与常规护理对预防PWH患者体重增加和糖尿病的干预。我们会 通过与惠康信托资助的非洲健康研究机构的现有合作开展这项研究 研究所(AHRI)。通过这段时间的培训和研究，我将处于有利的地位，以实现研究 独立性，并计划在该项目的第四年提交NIH R01申请，以测试 南非威斯康星医院预防体重增加和糖尿病的干预措施。

PROJECT SUMMARY Background: Obesity and diabetes are important risk factors for morbidity and mortality in people with HIV (PWH), especially in sub-Saharan Africa where health systems are already grappling with a rapid rise in metabolic disease. Dolutegravir (DTG)-based antiretroviral therapy (ART) has recently been adopted as the first-line regimen in most of the region, despite evidence that it is associated with excess weight gain. While the HIV care system offers a capable health systems platform, obesity and diabetes prevention is not a current focus of care paradigms. Candidate: I am a Clinical Fellow in Infectious Diseases at Massachusetts General Hospital and a physician-scientist with doctoral-level training in global health epidemiology and a strong track record of published observational research. However, my recent experiences caring for PWH have led to a desire to gain new skills in the design and execution of interventional trials to prevent metabolic disease in this population. My overarching career goal is to become an independent, NIH-funded physician-scientist with expertise in the metabolic complications of treated HIV, and in developing and testing clinical interventions to prevent these complications. Training: To achieve research independence, I will require additional training in 1) obesity medicine and diabetes prevention, 2) behavioral model-based intervention design, and 3) the conduct and analysis of clinical trials to prevent metabolic complications of HIV. Mentors: My training and research plans will be overseen by my primary mentor Dr. Mark Siedner, who has extensive mentoring experience and conducts both observational cohort studies and clinical trials in South Africa. Drs. Janet Lo (obesity medicine and diabetes prevention), Christina Psaros (behavioral model-based intervention design), and Deborah Wexler (the conduct and analysis of clinical trials) will serve as co-mentors to provide additional focused expertise. I will also receive annual feedback from my Scientific Advisory Board, which includes Drs. Rochelle Walensky, Naomi Levitt, Robert Parker, and Till Bärnighausen. Research: With guidance from my team of mentors, I will explore the metabolic effects of DTG among PWH in South Africa and develop and pilot an intervention to mitigate these complications through three specific aims: 1) To determine the behavioral correlates of weight change and glucose intolerance for PWH transitioning to DTG-based ART in South Africa; 2) To develop an acceptable and contextually appropriate intervention to prevent weight gain and diabetes in PWH on DTG-based ART in South Africa; and 3) To conduct a factorial-randomized feasibility study of interventions to prevent weight gain and diabetes among PWH on DTG-based ART versus usual care. We will carry out this research through existing collaborations with the Wellcome Trust-funded Africa Health Research Institute (AHRI). Through this period of training and research, I will be well positioned to achieve research independence and plan to submit an NIH R01 application in the fourth year of this project to test the efficacy of an intervention to prevent weight gain and diabetes in PWH in South Africa.